Literature DB >> 18591341

Possible role of imatinib in clinical pulmonary veno-occlusive disease.

M J Overbeek1, G P van Nieuw Amerongen, A Boonstra, E F Smit, A Vonk-Noordegraaf.   

Abstract

The platelet-derived growth factor receptor inhibitor imatinib has demonstrated clinical and haemodynamical improvement in both animal models of pulmonary hypertension (PH) and patients with PH. It has been suggested that anti-proliferative effects on pulmonary vascular smooth muscle cells are responsible for these beneficial effects. The current study describes a patient with pulmonary arterial hypertension associated with a suspected pulmonary veno-occlusive disease. Treatment with imatinib resulted in rapid clinical improvement and decrease of ground-glass opacities and lobular septal thickening on high-resolution computed tomography. Based on these findings and on in vitro effects of imatinib on permeability of the endothelium, the authors hypothesise that the rapid clinical outcome is partly due to effects of imatinib on vascular integrity.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18591341     DOI: 10.1183/09031936.00054407

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  25 in total

Review 1.  Pulmonary arterial hypertension associated with systemic sclerosis.

Authors:  Stephen C Mathai; Paul M Hassoun
Journal:  Expert Rev Respir Med       Date:  2011-04       Impact factor: 3.772

Review 2.  Therapy for pulmonary arterial hypertension associated with systemic sclerosis.

Authors:  Stephen C Mathai; Paul M Hassoun
Journal:  Curr Opin Rheumatol       Date:  2009-11       Impact factor: 5.006

Review 3.  [Therapy of pulmonary arterial hypertension].

Authors:  R Voswinckel; F Reichenberger; H Gall; W Seeger; F Grimminger; H A Ghofrani
Journal:  Internist (Berl)       Date:  2009-09       Impact factor: 0.743

Review 4.  Mechanisms of Cardiovascular Toxicity of BCR-ABL1 Tyrosine Kinase Inhibitors in Chronic Myelogenous Leukemia.

Authors:  Dakota Gustafson; Jason E Fish; Jeffrey H Lipton; Nazanin Aghel
Journal:  Curr Hematol Malig Rep       Date:  2020-02       Impact factor: 3.952

5.  Imatinib attenuates inflammation and vascular leak in a clinically relevant two-hit model of acute lung injury.

Authors:  Alicia N Rizzo; Saad Sammani; Adilene E Esquinca; Jeffrey R Jacobson; Joe G N Garcia; Eleftheria Letsiou; Steven M Dudek
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2015-10-02       Impact factor: 5.464

Review 6.  Targeting Abl kinases to regulate vascular leak during sepsis and acute respiratory distress syndrome.

Authors:  Alicia N Rizzo; Jurjan Aman; Geerten P van Nieuw Amerongen; Steven M Dudek
Journal:  Arterioscler Thromb Vasc Biol       Date:  2015-03-26       Impact factor: 8.311

7.  Evaluation of pulmonary hypertension in a child: role of computed tomography.

Authors:  Saurabh Kumar Gupta; Anita Saxena; Gurpreet Singh Gulati
Journal:  Indian J Pediatr       Date:  2011-05-28       Impact factor: 1.967

8.  Non-congenital heart disease associated pediatric pulmonary arterial hypertension.

Authors:  D D Ivy; J A Feinstein; T Humpl; E B Rosenzweig
Journal:  Prog Pediatr Cardiol       Date:  2009-12-01

9.  Characteristics of patients with pulmonary venoocclusive disease awaiting transplantation.

Authors:  Keith M Wille; Nirmal S Sharma; Tejaswini Kulkarni; Matthew R Lammi; Joseph B Barney; S Christopher Bellot; Ryan S Cantor; David C Naftel; Enrique Diaz-Guzman; David C McGiffin
Journal:  Ann Am Thorac Soc       Date:  2014-11

Review 10.  Using cultured endothelial cells to study endothelial barrier dysfunction: Challenges and opportunities.

Authors:  Jurjan Aman; Ester M Weijers; Geerten P van Nieuw Amerongen; Asrar B Malik; Victor W M van Hinsbergh
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2016-06-24       Impact factor: 5.464

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.